AMGN vs NVO: How Amgen and Novo Nordisk Compare (2026)
Short answer
AMGN (Amgen) and NVO (Novo Nordisk) are often compared because they share investment themes, but they are different businesses. Amgen (AMGN) is one of the world's largest biotechnology companies, developing, manufacturing, and selling human therapeutics primarily for serious illnesses. Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. Neither is universally better: pick by which thesis you are expressing and what you already own. This is descriptive, not a recommendation.
What does Amgen (AMGN) do?
Amgen (AMGN) is one of the world's largest biotechnology companies, developing, manufacturing, and selling human therapeutics primarily for serious illnesses. Its portfolio spans inflammation, oncology, cardiovascular disease, bone health, and rare diseases, with well-known products that have included Enbrel, Prolia and Xgeva, Repatha, Otezla, and a growing pipeline. Amgen pioneered large-scale recombinant-protein and antibody manufacturing and is a leader in biosimilars as older biologics lose patent protection. The 2023 acquisition of Horizon Therapeutics added rare-disease drugs such as Tepezza and Krystexxa. Amgen is also developing obesity and metabolic candidates, including investigational drugs in the GLP-1 class of weight-loss therapies. Headquartered in Thousand Oaks, California, and founded in 1980, Amgen is a member of the Dow Jones Industrial Average and returns substantial cash to shareholders through a growing dividend and buybacks.
What does Novo Nordisk (NVO) do?
Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. Its franchise centers on GLP-1 receptor agonists, most notably semaglutide, sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. Novo Nordisk also holds a long-standing leadership position in insulin and broader diabetes therapies, and maintains smaller franchises in rare blood and endocrine disorders. The company is headquartered in Bagsvaerd, Denmark, and is controlled by the Novo Nordisk Foundation through a dual-share structure. US investors typically access it through the NVO American Depositary Receipt listed on the New York Stock Exchange, which represents the Danish B shares. The explosive demand for GLP-1 drugs for both diabetes and weight loss has made Novo Nordisk one of Europe's most valuable companies, while also straining its manufacturing capacity for injectable medicines.
AMGN vs NVO: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Amgen is best understood through its own drivers, and Novo Nordisk through its. The useful comparison is which set of drivers and risks you want exposure to.
- AMGN drivers: Rare disease and Horizon assets; Obesity and metabolic pipeline.
- NVO drivers: GLP-1 obesity and diabetes demand; Pipeline and next-generation candidates.
AMGN or NVO: which should you pick?
The bottom line: AMGN vs NVO
AMGN and NVO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AMGN and NVO exposure against your real portfolio. It is not an investment adviser.
Build a basket around AMGN with Walnut
Use Amgen as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the difference between AMGN and NVO?
+
Amgen (AMGN) is one of the world's largest biotechnology companies, developing, manufacturing, and selling human therapeutics primarily for serious illnesses. Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is AMGN or NVO the better stock?
+
Walnut is informational, not investment advice. Neither is universally better; AMGN and NVO suit different views and risk levels. Compare what each does, how they make money, and the risks, then decide which fits your thesis and what you already own.
Should you own both AMGN and NVO?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both before you add the second.
What are the risks of AMGN vs NVO?
+
AMGN: Amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure. Drug development is high-risk: pipeline candidates, including its obesity programs, can fail in late-stage trials or face regulatory setbacks. US drug-pricing policy, including Medicare negotiation under the Inflation Reduction Act, pressures margins on key products. The Horizon acquisition added debt. Litigation, manufacturing, and safety risks are inherent to the industry. Verify the latest pipeline and revenue trends before drawing conclusions. NVO: Novo Nordisk is heavily concentrated in a single drug class, so any clinical setback, safety signal, or faster-than-expected competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound) and newer entrants directly threatens the core franchise. Manufacturing capacity has been a persistent constraint, limiting how much demand it can serve. US drug pricing, payer coverage decisions, and potential price negotiation add reimbursement risk to its largest market. As an ADR, NVO carries Danish krone currency exposure and is influenced by European regulation. Patent expiries and the eventual arrival of biosimilar or generic competition loom over the long-term semaglutide economics.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AMGN or NVO; figures are approximate and dated. Verify current data before investing.